Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 5, 2012

View Archived Issues

Wellstat Immuno Therapeutics prepares new polypeptides

Janssen Pharmaceutica discloses new antifungal agents

German team patents novel integrin ligands for the diagnosis of cancer

Secondary analysis of patient risk factors in the ARISTOLE trial for thromboembolic events

Results of the clinical evaluation of combination therapy for drug resistant melanoma

A new murine model for the study of acute inflammatory arthritis

Results of the clinical evaluation of a treatment for refractory chronic cough

AVEO Oncology and Astellas begin enrollment in tivozanib/paclitaxel combination trial

Neuren Pharmaceuticals presents novel monoclonal antibodies for cancer

Merck & Co. discloses novel agents for schizophrenia

Researchers at Sarepta Therapeutics present new peptide conjugates

EZN-2208, a pegylated drug conjugate for brain tumors

Bristol-Myers Squibb synthesizes new agents for HCV infection

Novel deuterated derivatives of PTZ disclosed by Balance Therapeutics

Genovax sells GX-301 cancer vaccine to Mediolanum Farmaceutici

New MMP-13 inhibitors divulged by Abbott Laboratories

Sunshine Biopharma completes studies of anticancer compound Adva-27a

Phase I study confirms safety and immunogenicity of HIV vaccine

FDA removes 32-mg single intravenous dose from ondansetron label

Primary endpoint met for phase III Northera trial

Theravance initiates phase II study of TD-9855 in fibromyalgia

Bayer HealthCare obtains European approval for new long-term contraceptive

BGP-15 shows promising prophylactic and therapeutic effect in collagen-induced arthritis

Phase III data presented for posttreatment relapse of MS

The development of a murine model to investigate common pediatric soft tissue sarcomas

Astellas' NDA for tacrolimus extended-release capsules accepted for review by FDA

uniQure and Benitec Biopharma enter cross-licensing agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...